Identification and management of hepatitis C patients in primary care clinics

American Journal of Gastroenterology

Volumn 98, Issue 3, 2003, Pages 639-644

  Shehab, Thomas M ^a   Orrego, Mauricio ^a   Chunduri, Renu ^a   Lok, Anna S F ^a,b  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MICHIGAN HOSPITALS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEPATITIS C ANTIBODY; LIVER ENZYME; VIRUS RNA;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DISEASE PREDISPOSITION; DOCUMENTATION; EVALUATION; FEMALE; HEPATITIS C; HUMAN; HUMAN TISSUE; LIVER BIOPSY; LIVER CIRRHOSIS; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; MANAGEMENT; MEDICAL EXAMINATION; MEDICAL RECORD; OUTPATIENT DEPARTMENT; PATIENT; PATIENT REFERRAL; PHYSICIAN; PRACTICE GUIDELINE; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; RISK FACTOR; SCREENING TEST; VIRUS DETECTION;

EID: 0037345681     PISSN: 00029270     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1572-0241.2003.07331.x     Document Type: Article

References (13)

1. Alter MJ, Kruszon-Moran D, Nainan OV, et al. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med 1999;341:556-62.
2. Powell DW, for the Hepatitis C Consensus Development Panel. National Institutes of Health consensus development conference panel statement: Management of hepatitis C. Hepatology 1997;26(suppl 1):2S-10S.
3. Wong JB, McQuillan GM, McHutchinson JG, Poynard T. Estimating future hepatitis C morbidity, mortality and costs in the United States. Am J Public Health 2000;90:1562-9.
4. Wiley TE, McCarthy M, Breidi L, et al. Impact of alcohol on the histological and clinical progression of hepatitis C infection. Hepatology 1998;28:805-9.
5. Centers for Disease Control and Prevention. Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease. MMWR 1998;47: 1-39.
6. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared to interferon alfa-2b plus ribavirin for the treatment of chronic hepatitis C: 24-week treatment analysis of a multicenter, multinational phase III randomized controlled trial. Hepatology 2000;32:552A (abstract).
7. Fried MW, Shiffman ML, Reddy KR, et al. Pegylated (40 kDa) interferon alfa-2a (Pegasys) in combination with ribavirin: Efficacy and safety results from a Phase III, randomized, actively controlled, multicenter study. Gastroenterology 2001; 120(suppl 1):289A (abstract).
8. McHutchison JG, Gordon SC, Schiff ER, et al. Interferon alpha-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Engl J Med 1998;339: 1485-92.
9. Poynard T, Marcellin P, Lee SS, et al. Randomized trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. Lancet 1998; 352:1426-32.
10. Shehab TM, Sonnad SS, Jeffries M, et al. Current practice patterns of primary care physicians in the management of patients with hepatitis C. Hepatology 1999;30:794-800.
11. Nicklin DE, Schultz C, Brensinger CM, Wilson JP. Current care of hepatitis C patients by primary care physicians in an integrated delivery system. J Am Board Fam Pract 1999;12: 427-35.
12. Shehab TM, Sonnad S, Lok ASF. Management of hepatitis C patients by primary care physicians: A nationwide survey. Hepatology 1999;30:209A (abstract).
13. Healey CJ, Chapmann RWG, Fleming K. Liver histology in hepatitis C infection: A comparison between patients with persistently normal and abnormal transaminase. Gut 1995;37: 274-8.